Mirum Pharmaceuticals (MIRM) Cash from Investing Activities (2019 - 2026)

Mirum Pharmaceuticals' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$11.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 28.29% year-over-year to -$11.6 million; the TTM figure through Mar 2026 stood at -$19.4 million (up 81.75% YoY), while the FY2025 annual figure was -$24.0 million, up 73.42% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$11.6 million, down from $1.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $50.5 million in Q2 2023, with the low at -$182.8 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is -$2.0 million (2023), against an average of -$13.2 million.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities soared 211.33% in 2022, then slumped 124007.69% in 2025.
• Mirum Pharmaceuticals' Cash from Investing Activities stood at $26.8 million in 2022, then tumbled by 107.47% to -$2.0 million in 2023, then soared by 132.05% to $641000.0 in 2024, then jumped by 56.94% to $1.0 million in 2025, then slumped by 1250.0% to -$11.6 million in 2026.
• Business Quant data shows MIRM's Cash from Investing Activities at -$11.6 million in Q1 2026, $1.0 million in Q4 2025, and -$2.2 million in Q3 2025.